Tags

Type your tag names separated by a space and hit enter

[Pathophysiology and therapy of L-Dopa-induced dyskinesia].
Rev Neurol (Paris). 2003 Dec; 159(12):1125-42.RN

Abstract

Involuntary movements, or dyskinesias, represent a debilitating complication of levodopa therapy for Parkinson's disease. Dyskinesia is, ultimately, experienced by the vast majority of the patients. Despite the importance of this problem, little was known about the cause of dyskinesia, a situation that has dramatically evolved in the last few years. The present review presents: 1) the current understanding of dyskinesia pathophysiology and 2) the therapeutic modalities, mainly non-dopaminergic, available or in development. We here show that the questions raised by the dyskinesia may have a clinically-driven pharmacological answer: the symptomatic treatment of dyskinesia, the prevention of the priming and the de-priming of the neural networks.

Authors+Show Affiliations

Unité de Recherche en Neurosciences, Centre de Recherche du CHUQ, Université Laval, Ste-Foy, Québec, Canada.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

fre

PubMed ID

14978413

Citation

Hadj Tahar, A, et al. "[Pathophysiology and Therapy of L-Dopa-induced Dyskinesia]." Revue Neurologique, vol. 159, no. 12, 2003, pp. 1125-42.
Hadj Tahar A, Bézard E, Grondin R, et al. [Pathophysiology and therapy of L-Dopa-induced dyskinesia]. Rev Neurol (Paris). 2003;159(12):1125-42.
Hadj Tahar, A., Bézard, E., Grondin, R., Gross, C. E., & Bédard, P. J. (2003). [Pathophysiology and therapy of L-Dopa-induced dyskinesia]. Revue Neurologique, 159(12), 1125-42.
Hadj Tahar A, et al. [Pathophysiology and Therapy of L-Dopa-induced Dyskinesia]. Rev Neurol (Paris). 2003;159(12):1125-42. PubMed PMID: 14978413.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Pathophysiology and therapy of L-Dopa-induced dyskinesia]. AU - Hadj Tahar,A, AU - Bézard,E, AU - Grondin,R, AU - Gross,C E, AU - Bédard,P J, PY - 2004/2/24/pubmed PY - 2004/10/9/medline PY - 2004/2/24/entrez SP - 1125 EP - 42 JF - Revue neurologique JO - Rev Neurol (Paris) VL - 159 IS - 12 N2 - Involuntary movements, or dyskinesias, represent a debilitating complication of levodopa therapy for Parkinson's disease. Dyskinesia is, ultimately, experienced by the vast majority of the patients. Despite the importance of this problem, little was known about the cause of dyskinesia, a situation that has dramatically evolved in the last few years. The present review presents: 1) the current understanding of dyskinesia pathophysiology and 2) the therapeutic modalities, mainly non-dopaminergic, available or in development. We here show that the questions raised by the dyskinesia may have a clinically-driven pharmacological answer: the symptomatic treatment of dyskinesia, the prevention of the priming and the de-priming of the neural networks. SN - 0035-3787 UR - https://www.unboundmedicine.com/medline/citation/14978413/[Pathophysiology_and_therapy_of_L_Dopa_induced_dyskinesia]_ DB - PRIME DP - Unbound Medicine ER -